BioStock Investor Meeting: Elicera Therapeutics presents
Gothenburg-based Elicera Therapeutics, headed by CEO Jamal El-Mosleh, travelled to Stockholm to present the company at the BioStock Investor Meeting. The cell and gene therapy company has developed a universal CAR T-cell-enhancement technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to be used in the fight against cancer.
See Elicera Therapeutics’ presentation below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
